Specific

biomarkers are consistently associated with higher probability of disease in

some fetuses, but not all, indicating risk

Biomarker

detection allows for effective treatment of the fetus prior to birth

Absence

of a biomarker means that the corresponding disease will definitely not develop

in the fetus

The

presence of a biomarker confirms that a disease is present in all fetuses

expressing it, allowing definitive diagnosis

Hypoxia

directly generates ROS, which independently cause fetal growth restriction

without involvement of other placental factors

Maternal

systemic hypoxia alone causes placental hypoxia and fetal growth restriction,

without involvement of placental blood flow or local signalling

Excess

ROS production causes hypoxia in the placenta, which then triggers fetal growth

restriction

Reduced

placental blood flow leads to hypoxia, which triggers secretion of factors that

limit fetal growth, while also increasing ROS that exacerbate placental

dysfunction

Absence

of a biomarker ensures that the fetus will never develop the associated disease

Certain

biomarker profiles are associated with an increased likelihood of disease

outcomes in a subset of fetuses, without perfectly predicting disease in all

cases

Measurement

of biomarkers directly enables prevention of disease through immediate

intrauterine therapy

Detection

of a biomarker guarantees that a specific disease is already present in the

fetus

Individuals

with low nephron number show higher rates of hypertension in adulthood

Prematurely

born infants are more likely to develop diabetes later in life

Poor

nutrition during gestation reduces nephron number at birth

Low

nephron number is associated with reduced kidney size

Podocyte

density is reduced in low-nephron individuals without changes in filtration or

blood pressure

Individuals

with fewer nephrons exhibit increased SNGFR per nephron, glomerular hypertrophy

with reduced podocyte density, higher rates of glomerulosclerosis, and elevated

blood pressure

Increased

SNGFR occurs without changes in glomerular size, podocyte density, or blood

pressure

Individuals

with fewer nephrons show proportionally reduced filtration without structural

changes and normal blood pressure

Adult

disease risk is primarily determined by genetics, with little influence from

prenatal or early postnatal environment

Low

birth weight infants of both sexes show uniform adult disease outcomes, and

early postnatal nutrition fully restores organ function

Individuals

exposed to maternal undernutrition during gestation exhibit reduced nephron

number, altered cardiovascular physiology, and increased adult disease risk,

with sex-specific differences in severity

Accelerated

postnatal weight gain eliminates all developmental deficits caused by prenatal

stress, without sex differences

Individuals

with lower nephron number have higher SNGFR in remaining nephrons, glomerular

hypertrophy with reduced podocyte density, and are likely to develop glomerulosclerosis

and higher blood pressure

Individuals

with lower nephron number have normal SNGFR, reduced podocyte density, but no

change in glomerulosclerosis or blood pressure

Individuals

with lower nephron number have proportionately reduced SNGFR, preserved

podocyte density, no glomerulosclerosis, and normal blood pressure

Individuals

with lower nephron number have higher SNGFR but maintain podocyte density and

show no increase in glomerulosclerosis or blood pressure

Nephron

number gradually declines during the normal aging process

Maternal

undernutrition during pregnancy decreases nephron formation

Individuals

with reduced nephron number tend to have smaller kidneys at birth

Adults

with low nephron number show a higher prevalence of hypertension

Random

technical variation in nephron counting methods

Differences

in adult kidney size due to body habitus

Differences

in fetal growth conditions and maternal health during pregnancy

Age-related

nephron loss occurring decades after birth